2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.63 (Poster) A comparative analysis of plasma genotyping practices in non-small cell lung cancer by race, ethnicity, and smoking status

PP01.63 (Poster) A comparative analysis of plasma genotyping practices in non-small cell lung cancer by race, ethnicity, and smoking status

Back to course

Pdf Summary

This study aimed to analyze the practice of plasma genotyping in non-small cell lung cancer (NSCLC) patients by race, ethnicity, and smoking status. Plasma genotyping, which offers advantages such as accessibility, rapid turnover, and capturing tumor genetic heterogeneity, has no consensus regarding its role in managing advanced NSCLC.<br /><br />A retrospective analysis was conducted on NSCLC patients who underwent plasma genotyping between 2015 and 2022 in three hospitals. The data, including tissue genotyping, was obtained from the electronic health records (EHR) using the Precision Medicine Analytics Platform (PMAP) and supplemented with chart annotation. Statistical analyses were performed using chi-square tests and Kaplan-Meier analyses.<br /><br />The results showed no significant difference in plasma genotyping compared to combined plasma and tissue genotyping in terms of race, smoking status, age, and the receipt of matched therapy. These findings suggest that plasma genotyping may achieve similar identification rates of actionable molecular alterations as the current gold standard tissue-based genotyping.<br /><br />Further research is needed, particularly in underrepresented groups, and in comparison to patients who did not undergo either testing. The study emphasizes the importance of consistent and equitable genomic testing practices to avoid disparities in NSCLC management.<br /><br />References:<br />1. Cainap, Calin, et al. "Next Generation Sequencing Technology in Lung Cancer Diagnosis." Biology 10.9 (2021).<br />2. Howlader, Nadia, et al. "The Effect of Advances in Lung-Cancer Treatment on Population Mortality." The New England Journal of Medicine 383.7 (2020): 640-649.<br />3. Leighl, Natasha B., et al. "Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer." Clinical Cancer Research 25.15 (2019): 4691-4700.<br />4. Shin, Donghoon, et al. "The Impact of Social Determinants of Health on Lung Cancer Screening Utilization." Journal of the American College of Radiology 19.1 (2022): 122-130.<br />5. Si, Han, et al. "A Blood-Based Assay for Assessment of Tumor Mutational Burden in First-Line Metastatic NSCLC Treatment: Results from the MYSTIC Study." Clinical Cancer Research 27.6 (2021): 1631-1640.

Asset Subtitle

Vivian Altiery De Jesus

Keywords

plasma genotyping

non-small cell lung cancer

NSCLC

race

ethnicity

smoking status

tumor genetic heterogeneity

retrospective analysis

actionable molecular alterations

genomic testing practices